Trevi Therapeutics, Inc. (TRVI) SEC Filings, Mar-May 2026

Trevi Therapeutics reported a net loss of $13.2 million for the three months ended March 31, 2026, compared with $10.3 million a year earlier, as it advances its chronic cough drug Haduvio. Research and development expenses rose to $9.9 million, driven by Phase 3 preparation in idiopathic pulmonary fibrosis (IPF), Phase 2b work in refractory chronic cough (RCC) and NDA‑supportive studies, while general and administrative costs increased to $5.0 million.

The company ended the quarter with $171.8 million in cash, cash equivalents and marketable securities, and subsequently strengthened its balance sheet through an April 2026 underwritten equity offering that generated gross proceeds of $173.4 million and approximately $162 million in net proceeds. Management believes existing resources will fund operations for at least 12 months as Trevi progresses parallel Phase 3 IPF-related chronic cough trials, a Phase 2b RCC trial, a Phase 2b non‑IPF ILD trial and multiple Phase 1 studies.

Trevi Therapeutics, Inc. reported a first quarter 2026 net loss of $13.2 million, or $0.09 per share, as it increased investment in its chronic cough pipeline. Research and development and general and administrative expenses both rose versus the prior-year period.

The company ended the quarter with $171.8 million in cash, cash equivalents and marketable securities and then completed an underwritten common stock offering in April 2026 that generated approximately $162 million in net proceeds. Trevi now expects its cash runway to extend into 2030, supporting Phase 3 trials in IPF-related chronic cough, Phase 2b trials in non-IPF ILD-related chronic cough and refractory chronic cough, and a potential FDA submission for Haduvio.

Trevi Therapeutics, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 3, 2026. Holders of common stock as of April 6, 2026, when 128,586,792 shares were outstanding, may vote online.

Proposals include electing one Class I director, ratifying Ernst & Young LLP as auditor for 2026, an advisory “say‑on‑pay” vote, and approving an amended and restated 2019 Stock Incentive Plan that adds 8,000,000 shares to the equity pool. Stockholders are also asked to approve doubling authorized common stock from 200,000,000 to 400,000,000 shares. The board unanimously recommends voting in favor of all proposals.

Trevi Therapeutics is offering 11,600,000 shares of common stock at a public offering price of $13.00 per share, for aggregate gross proceeds of $150,800,000. The underwriters have a 30-day option to purchase up to an additional 1,740,000 shares. Net proceeds are estimated at approximately $141.1 million (no exercise) and $162.4 million (full exercise), after deducting underwriting discounts and commissions. The offering is expected to settle on or about April 20, 2026. Shares outstanding were 128,306,056 as of December 31, 2025. Trevi estimates approximately $171.8 million in cash, cash equivalents and marketable securities as of March 31, 2026 (preliminary). Proceeds are intended to fund Haduvio clinical development (Phase 3 IPF program, Phase 2b non-IPF ILD and RCC trials), working capital and general corporate purposes; Trevi states these resources are expected to be sufficient to fund operations through 2029, based on current plans.

Trevi Therapeutics entered an underwriting agreement for an underwritten public offering of 11,600,000 shares of common stock at $13.00 per share, all sold by the company. Underwriters will buy the shares at $12.22 per share, and have a 30-day option to purchase up to 1,740,000 additional shares at the same terms.

Trevi estimates net proceeds of about $141.1 million, or $162.4 million if the option is fully exercised, to be raised under its effective Form S-3 shelf. It estimates cash, cash equivalents and marketable securities of approximately $171.8 million as of March 31, 2026, and believes existing cash plus offering proceeds will fund operations and planned Haduvio clinical trials through 2029, though not commercialization or all indications, so additional capital will still be required.

Trevi Therapeutics is offering $150,000,000 of common stock, subject to completion. The preliminary prospectus supplement states the underwriters have a 30-day option to purchase up to an additional $22,500,000 of shares. Trevi estimates approximately $171.8 million in cash, cash equivalents and marketable securities as of March 31, 2026. The company plans to use proceeds to fund Haduvio clinical development, including two pivotal Phase 3 trials and other trials described in the prospectus supplement.

Trevi Therapeutics, Inc. is soliciting proxies for its 2026 virtual Annual Meeting of Stockholders to be held June 3, 2026.

Stockholders will vote on six items, including the election of one Class I director, ratification of Ernst & Young LLP as auditor, an advisory approval of executive compensation, approval of an Amended and Restated 2019 Stock Incentive Plan adding 8,000,000 shares, and an amendment to increase authorized common shares from 200,000,000 to 400,000,000.

Only holders of common stock as of the record date, April 6, 2026, may vote; the proxy materials note 128,586,792 shares issued and outstanding as of that record date and report 128,411,048 shares outstanding as of March 31, 2026.

Trevi Therapeutics Inc: An amended Schedule 13G/A filed by The Vanguard Group reports zero shares beneficially owned and 0% of the class as of the filing. The filing explains an internal realignment at The Vanguard Group, Inc. on January 12, 2026 that led certain subsidiaries to report separately.

The filing is administrative: it lists Vanguard's address and states Vanguard and related investment vehicles have the right to receive dividends or proceeds where applicable, and certifies that no single other person holds more than 5% of the class. The form is signed on 03/27/2026.